Kaleo Logo

News

Media Contact

Caryn Foster Durham
Senior Director, Corporate Communications
(804) 545-6360
mediainquiries@kaleo.com

Media Contact

Caryn Foster Durham
Senior Director, Corporate Communications
(804) 545-6360
mediainquiries@kaleo.com

August 2, 2022

Kaléo Enters Into Licensing Agreement With Valeo Pharma For The Canadian Rights to ALLERJECT®(epinephrine injection, USP)

Accent Lines

Richmond, Va (August 2, 2022)Kaléo, a privately held U.S. pharmaceutical company, today announced that

it has entered into a ten-year License, Supply, and Commercialization agreement with Valeo Pharma, a

Canadian pharmaceutical company, for the Canadian rights to ALLERJECT® (epinephrine injection, USP) for the

treatment of severe allergic reactions.

“Patients with life threatening allergies across Canada deserve access to this innovative and potentially

lifesaving product,” said Kaléo President and CEO Ronald Gunn. “Valeo Pharma’s sales force, relationships with

the healthcare community, and commitment to patients make them the ideal partner for ALLERJECT.”

For more information please visit valeopharma.com/news.